cyrilzakka/clinical-trials huggingface dataset:
Safe Time for Apnea After Preoxygenation

The use of 100% oxygen during the induction of general anesthesia is always preferable to have enough time to secure the airway by endotracheal intubation, because preoxygenation with a low oxygen concentration may reduce the safe time for apnea. However, using a low oxygen concentration during preoxygenation might prevent the formation of atelectasis. There is still no clear conclusion about the best oxygen concentration for preoxygenation. Our study is designed to evaluate the safety of preoxygenation with 80%, 60%, 40%, 30% and 21% oxygen by the safe time for apnea during the induction of general anesthesia.

We decide to add 3 groups (80%, 60%, and 40% oxygen) in our study to fully evaluate the safety of preoxygenation with different oxygen concentration.

Zijia Li 2018.3.2

Eligibility Criteria:
Inclusion Criteria:

* Nonsmoking patients aged 18 years to 60 years
* Undergoing general anesthesia for elective surgery
* Pulse oxygen saturation ≥95% when breathing air quietly in bed
* American Society of Anesthesiologists(ASA) physical status class I-II
* Informed consent can be obtained

Exclusion Criteria:

* A suspected difficult airway
* Be allergic to midazolam, propofol , fentanyl or Cisatracurium
* Severe disease of respiratory system or cardiovascular system,or obstruction of the digestive tract
* Oxygen reserve is suspected low,or patient who does not tolerate hypoxemia well
* A history of mental disorder or patient who can not collaborate well
* Body mass index more than 30 kg/㎡
The Greek Acute Dance Injuries Registry

Dance is a highly demanded physical activity with a high rate of acute and emergent events (AEE). No systematic prospective study has been conducted in any Greek population of dance students for the registration of the AEE and their possible predisposing factors. This is a prospective cohort study, the purpose of which is to register the AEE risk factors, their long-term follow-up, and the potential AEE during an academic year in adult dance students in Athens, Greece.

Dance, as a physical activity, is considered as one of the most demanding activities at a young age with a high rate of acute and emergent events (AEE). Although dancers perform movement combinations that require high athletic ability, often their physical fitness levels appear to be unexpectedly low and the majority of them will experience at least one injury a year. Determination of the AEE predisposing factors in dancers is necessary to reduce their percentage rates, and until now no systematic prospective study has been conducted in a Greek population of vocational dance schools' students to register both the AEE themselves and their possible predisposing factors.

The primary objective of the study is to register the risk factors for the AEE occurrence in students at Higher Vocational Schools of Dance in Athens and their long-term follow-up. Secondary objectives are to register potential AEE during an academic year and to investigate possible correlations of the above parameters, both among themselves and with socio-demographic, anthropometric, psychometric and medical characteristics of the sample. Finally, a translation and cross-cultural adaptation to a Greek population of the Dance Functional Outcome Survey (DFOS) scale will be carried out.

This is a prospective cohort study with the study population being adult students of 8 Higher Vocational Schools of Dance in Athens. A registration of socio-demographic, anthropometric and medical characteristics, as well as an electrocardiogram, will be carried out at the beginning of the academic year. Core stabilization, balance, body composition, aerobic capacity, dance motor control, dance functional ability, quality of life, fatigue, depressive symptoms, anxiety, stress, performance satisfaction, risk for developing eating disorders, athletic burnout, and predisposition to psychological flow will be registered at the beginning and at the end of the academic year.

Eligibility Criteria:
Inclusion Criteria:

* Undergraduate student in one of the eight Higher Vocational Dance Schools of the study
* Age ≥18 years
* Ability to understand, write and speak Greek
* Written consent for participating into the study

Exclusion Criteria:

* Student listener who is not officially participating to the whole educational program
* Pregnancy
* Deny to participate and/or give a written consent for participating into the study
Evaluation of the Effect of Different Rapid Maxillary Expansion Appliances on Airway by Acoustic Rhinometry

Rapid maxillary expansion (RME) is an orthodontic treatment based on the principle of opening the midpalatal suture with the effect of orthopedic forces. The aim of this randomized clinical study was to evaluate and compare the effects of tooth-borne, tooth-tissue borne, and bone-borne rapid maxillary expanders on nasal airway by using AR. The null hypothesis was that there is no difference for the effect on nasal airway between the appliances.

Introduction: The aim of this 3-arm parallel trial was to compare the effects of tooth-borne (Hyrax), tooth tissue-borne (KBME) and bone-borne (MIDME) rapid maxillary expansion (RME) appliances on nasal airway with acoustic rhinometry (AR).

Methods: Fourty-six 12- to 14-years-old patients with narrow maxilla were randomly allocated into 3 study groups according to the type of RME appliance: tooth-borne, tooth tissue-borne and bone-borne. Participants were recruited from the Department of Orthodontics, Faculty of Dentistry, Izmir Katip Celebi University, Turkey. During the RME treatment, the same protocol was applied to all patients and the expansion screws were activated twice a day (0.4 mm/day). Computer-generated randomization was used with group allocation concealed using opaque, sealed envelopes. The outcome assessor was blinded; however, it was not feasible to blind either operator or patients. The primary outcome of this study was the correction of posterior crossbite. Secondary outcomes included AR assessment of nasal airway dimensions as nasal volume, the minimal cross-sectional area (MCA) 1 and 2. AR measurements were obtained before treatment (T0), after active expansion (T1), and at 3 months-follow-up (T2). One-way analysis of variance (ANOVA) and a Bonferroni test was used for inter-group comparison and two-way ANOVA was used for intra-group evalaution.

Eligibility Criteria:
Inclusion Criteria:

1. no previous tonsillar, nasal or adenoid surgery and orthodontic treatment,
2. Bilateral crossbite and need for RME,
3. maxillary and mandibular permanent teeth fully erupted,
4. willingness to participate in the study

Exclusion Criteria:

1. the presence of adenotonsillectomy due to tonsillar hypertrophy or adenoidal hypertrophy
2. having nasal/nasopharyngeal /oropharyngeal pathologies, craniofacial syndromes, systemic disease, poor oral hygiene,
3. history of previous orthodontic treatment.
Fractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting

Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. The goal of this clinical trial is to learn whether Fraction Flow Reserve (FFR) is appropriate to determine stenting in hypertension patients with atherosclerosis renal artery stenosis. The main questions it aims to answer are:

* Is it appropriate to use FFR to determine whether or not stenting for hypertension patients with atherosclerosis renal artery stenosis?
* To provide detailed data supporting design of further trial, such as sample size calculating, cut-off value for FFR in renal artery stenosis, etc.

Participants met the inclusive/exclusive criteria will be randomized to stenting or not in the renal artery, then hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, randomization will be applied. If FFR is \<0.80, randomization will be ignored, and stenting will be performed as planned. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.


Eligibility Criteria:
Inclusion Criteria:

* With recorded hypertension, AND the blood pressure is not controlled (SBP ≥140mmHg and/or DBP ≥90mmHg) on 2 or more classes of anti-hypertensive drugs;
* Evidence of renal artery stenosis and undergoing renal artery angiography;
* Able to follow the study protocol and provide informed consent;
* Renal artery angiography shows at least 1 main artery with stenosis of 50%-90%, AND the diameter is ≥ 4.0mm.

Exclusion Criteria:

* SBP ≥200mmHg and/or DBP ≥120mmHg at the day or randomization;
* Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis;
* Pregnancy or unknow pregnancy status in female of childbearing potential;
* Participation in any drug or device trial during the study period;
* Any stroke/TIA, OR with ≥70% stenosis of carotid artery;
* Any major surgery, myocardial infarction or interventional therapy 30 days prior to study entry;
* LVEF \<30%;
* Comorbid condition causing life expectancy ≤1 year;
* Allergy to contrast or any of the following: aspirin, clopidogrel;
* Previous kidney transplant;
* Previous renal artery bypass surgery or stent intervention;
* Kidney size less than 8 cm measured by ultrasound;
* Local lab serum Cr \>3.0 mg/dl (265.2μmol/l) on the day of randomization;
* Reference vessel size \<4 mm or \>8 mm.
Inflammatory Cardiomyopathy Baseline Cohort (SFB/TR19)

cohort of cardiomyopathy patients (suspected or validated inflammatory cardiomyopathy) recruited at baseline by the SFB-TR19 project. Standardized protocols used for the assessment of medical history and examinations, laboratory biomarkers, and the collection of various biosamples for biobanking purposes.


Eligibility Criteria:
Inclusion Criteria:

* suspected inflammatory cardiomyopathy at baseline

Exclusion Criteria:

* none
Study to Reduce Symptoms of Premature Beats With Ranolazine

Investigate whether ranolazine, a novel anti-anginal agent with antiarrhythmic properties, has a role in the management of symptomatic ventricular premature beats.

The main objective is to compare the effect of ranolazine versus placebo on premature ventricular beats (using 24-hour ambulatory electrocardiographic monitoring) for subjects with symptomatic palpitations. Subject population will consist of seventy-two adult subjects of both sexes who have greater than 1,000 premature ventricular beats during initial monitoring.

Eligibility Criteria:
Inclusion Criteria:

* Subjects male and female 18 years and older
* Symptoms of palpitations
* Greater than or equal to 1,000 Ventricular Premature Beats during 24-hour electrocardiographic monitoring
* Completion of a consent form prior to pre-randomization Holter monitor

Exclusion Criteria:

* Moderate to severe symptomatic heart failure, New York Heart Association Class III/IV
* Moderate to severe symptomatic angina, Canadian Cardiovascular Classification III/IV
* Moderate to severe structural heart disease in the absence of an implantable cardiac defibrillator in a subject who would otherwise be eligible for a defibrillator (e.g. history of myocardial infarction and a left ventricular ejection fraction less than 30%)
* Clinically significant hepatic disease (cirrhosis or chronic hepatitis) or abnormal liver associated enzymes greater than three times the upper limits of normal
* A baseline corrected QT interval greater than or equal to 500msec or history of congenital channelopathy (long QT syndrome, Brugada syndrome) or torsades de pointes.
* Treatment with agents known to prolong the QTc interval
* Treatment with agents that are potent or moderately potent inhibitors of CYP3A, to include, but is not limited to the following: ketoconazole, HIV protease inhibitors (i.e. ritonavir), macrolide antibiotics (i.e. clarithromycin), diltiazem and verapamil
* Females who are pregnant, planning to get pregnant, or breast feeding ( females under the age of 55 years who have not previously undergone surgical sterilization procedures will have serum qualitative pregnancy testing)
* Thyroid stimulating hormone less than 0.27 IU/mL
* Serum magnesium less than 1.5mg/dL
* Serum potassium less than 3.5 mEq/dL or greater than 5.0 mEq/dL
* Estimated GFR less than 30 mL/min
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety

To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety.

Clinical study phase III, multicenter, prospective, open.

Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients who achieve scores between 18 and 29 points in the Hamilton Scale for Anxiety;
* Individuals of any ethnic group male and female, aged above 18 years;
* Consent of the subject of research (a consent form signed).

Exclusion Criteria:

* Patients with known hypersensitivity to any components of the formula;
* Pregnant women and nursing mothers;
* Patients with endogenous depression, schizophrenia, suicidal tendency;
* Patients with heart disease unabated, unabated kidney, liver and lung unabated unabated, at the discretion of the investigator;
* Addiction to drugs, including alcohol, at the discretion of the investigator;
* Patients who are using any medication that could interfere with the effect of the drug under study;
* Impossibility of compliance to the protocol
Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle

This study aims to analyze outcomes of patients with systemic right ventricle (SRV) implanted with Cardiac Resynchronization Therapy (CRT) systems and to compare the impact of CRT in SRV patients with other congenital heart diseases (CHD).

Heart failure is henceforth the main cause of death in adult patients with congenital heart disease (CHD). The number of affected patients is expected to continue to grow exponentially due to the important increase and aging of this population.

In symptomatic patients despite optimal pharmacological therapy, Cardiac Resynchronization Therapy (CRT) offers a well-recognized therapeutic option in dilated and ischemic cardiomyopathies with severely impaired left ventricle ejection fraction and complete left bundle branch block. In patients with CHD, the level of evidence is much more limited. Underlying phenotypes are heterogeneous, including systemic right ventricles (SRVs), isolated sub-pulmonary right ventricle dysfunctions, single ventricles, and most of patients have a right bundle branch block. All these specificities question the extrapolation of data reported in patients with acquired cardiomyopathies. Despite the lack of evidence, CRT systems have been progressively used in CHD patients, also because alternative options are poor, mainly represented by cardiac transplantation, but grafts are rare and congenital patients frequently have contraindications.

A positive impact of CRT in CHD has first been suggested in small series where hemodynamic invasive parameters (e.g. dP/dt max) were improved and QRS narrowed by multisite pacing. A few subsequent studies then reported an improvement of ventricular functions and patient-reported functional subjective parameters (mainly NYHA classification). However, the number of patients included in most studies was limited and heterogeneous forms of CHD were often pooled when interpreting results. The studies evaluating CRT specifically in patients with SRV are very rare and demonstrated conflicting results. The largest study to date assessing specifically CRT in patients with SRV included 20 patients with congenitally corrected transposition of the great arteries (cc-TGA) and demonstrated an acute improvement in two-thirds of patients.

Although patients with SRV represent one of the main groups of CHD patients currently implanted with CRT, the paucity of specific data in this population has been highlighted as a major evidence gap and as a high-impact research question by the American Heart Association/American College of Cardiology guidelines committee.

Eligibility Criteria:
Inclusion Criteria:

* All patients with congenital heart disease and CRT device

Exclusion Criteria:

* Patient's refusal
Multiple Myeloma Minimal Residual Disease

Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease


Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years
* previously undiagnosed myeloma
* eligible for high dose therapy and bone marrow transplantation
* signed consent

Exclusion Criteria:

* ongoing therapy for another neoplasia
* Patients with other hematologic malignancies,
* patients deprived of liberty for administrative or judicial reasons
* previously treated for myeloma
Impact of Lung Flute Therapy on Asthma

We hypothesized that the ability of the Lung Flute to enhance mucus clearance from the lower airways could be used to improve asthma control, if the device is used on a chronic basis. The primary end point of the study is the comparison of Asthma Control Test (ACT) - a validated questionnaire for asthma control and exhaled NO before, during and after using the lung flute. Several secondary end points were assessed for efficacy and safety, including health status, spirometric lung function, "stepping down" controller therapy and daily albuterol use.

This is a 3 month open label study. We plan to enroll 48 subjects with asthma at the Buffalo General Medical Center Allergy Clinic or the office of Dr. James Cumella. Inclusion criteria includes: at least 12 years of age, diagnosis of asthma and no current or previous history of smoking. Exclusion criteria includes: exacerbation of asthma or hospitalization for asthma within 8 weeks prior to enrollment, predominant chronic obstructive pulmonary disease (COPD) and bronchiectasis by clinical and/or radiological assessment, history of cough syncope, pregnant or nursing women, and inability to comply with study procedures.

Eligibility Criteria:
Inclusion Criteria:

* at least 12 years of age
* diagnosis of asthma and no current or previous history of smoking.

Exclusion Criteria:

* exacerbation of asthma or hospitalization for asthma within 8 weeks prior to enrollment
* predominant COPD and bronchiectasis by clinical and/or radiological assessment
* history of cough syncope
* pregnant or nursing women
* not fluent in English
* inability to comply with study procedures.
Factors Affecting Caloric Regulation in Human Feeding

This study will test the hypothesis that reducing the energy density of the diet by incorporating more water-rich foods will result in: 1) greater weight loss and weight maintenance; 2) greater diet satisfaction and satiety; and 3) more healthful dietary patterns than reducing dietary fat alone.

Energy density refers to the amount of calories (energy) in a given weight of food. For the same amount of energy, a larger volume (weight) of food can be consumed if the food or diet is low in energy density than if the food or diet is high in energy density. The two nutrients that have the largest impact on energy density are fat and water. Foods high in fat and low in water content are typically high in energy density, whereas foods low in fat and high in water content, such as fruits and vegetables, are low in energy density. This study will examine whether there are increased benefits for weight loss and weight maintenance when the ad libitum consumption of water-rich foods is added to a reduced-fat diet, thus making it even lower in energy density.

Comparisons: Reduced-energy-dense diet and Reduced-fat diet

Eligibility Criteria:
Inclusion Criteria:

* Healthy women
* BMI (body mass index) 30 through 40 kg/m2
* Normal blood pressure
* LDL (low density lipoprotein)-cholesterol \< 90th percentile recommendations
* Triglycerides, fasting blood glucose, and all other blood values within normal ranges
* Able to participate in low to moderate physical activity.

Exclusion Criteria:

* Heart disease
* Diabetes - type I or II
* High blood pressure
* Renal or kidney disease
* Gastrointestinal disease
* Blood clotting disorder
* Liver disease or cirrhosis
* Any oral steroids
* Gout (requiring treatment)
* Anemia
* Lung disease
* Cancer within the last 5 years
* Thyroid disease
A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

To develop and validate a CT-based transfer learning radiomics model for predicting response to initial TAE in GEP-NETLM patients and compare its performance with traditional radiomics and clinical models.


Eligibility Criteria:
Inclusion Criteria:

* (a) Clinical diagnosed as gastroenteropancreatic neuroendocrine tumor liver metastases; (b) Received initial transarterial embolization therapy; (c) Underwent multi-phase ceCT scans pre-TAE (≤1 month) and post-TAE (4-6 weeks).

Exclusion Criteria:

* (a) Neuroendocrine carcinoma (NEC) or other malignancies. (b) Received other liver metastasis treatments. (c) Lack of Multi-phase ceCT scans records. (d) CT images with artifacts or no visible lesions.
Variables Predicting Reintubation After Thymectomy in Patients With Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune disease that is characterized by muscle weakness and fatigue. The role of the thymus in MG has been suggested by the evidence that 10% to 15% of patients present with a thymoma and at least 60% with thymus hyperplasia or dysplasia.Beneficial effects of thymectomy in patients with MG have been described in 40% to 90%.Few studies have looked at the incidence of reintubation (not just within 24 hours after extubation), the factors associated with reintubation, and patient outcome.

Premature extubation may lead to hypercarbia, hypoxemia, pulmonary hypertension, right heart failure, and myocardial ischemia. Additionally, it subjects the patient to the physical risks of reintubation, including esophageal intubation, laryngeal trauma, and pulmonary aspiration. The purpose of the present study was to determine the incidence of reintubation, the variables associated with reintubation, and patient outcome

Inclusion was based on the availability of all the following possible predictive pre-operative variables: age, gender, weight, height, body mass index, diabetes, creatinine, duration of MG, severity of MG (based on Osserman's classification), pathological type of MG, history of myasthenic crisis, dose of pyridostigmine, use of a steroid hormone, and use of an immunosuppressant.operative variables: postoperative pulmonary infection, total duration of hospital stay, duration of ICU stay, and duration of postoperative hospital stay. Variables were collected by research assistants and maintained in a computer database.

Eligibility Criteria:
Inclusion Criteria:

* younger than 75 years
* absence of heart failure as the primary indication for mechanical ventilation •Acute Physiology and Chronic Health Evaluation (APACHE) II score less than 12 points on day of extubation
* body mass index less than 30

Exclusion Criteria:

•preoperative moderate-to-severe chronic obstructive pulmonary disease